Definium Therapeutics (NASDAQ:DFTX) Reaches New 52-Week High – Here’s What Happened

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $40.02 and last traded at $40.02, with a volume of 2749393 shares trading hands. The stock had previously closed at $24.48.

Wall Street Analyst Weigh In

DFTX has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Oppenheimer restated an “outperform” rating and set a $40.00 target price on shares of Definium Therapeutics in a research report on Thursday, April 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Leerink Partners lifted their price target on shares of Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Finally, Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 16th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $37.92.

Definium Therapeutics Price Performance

The business’s 50 day moving average is $22.68 and its 200-day moving average is $18.40. The firm has a market capitalization of $3.58 billion, a P/E ratio of -14.41 and a beta of 2.37. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, sell-side analysts predict that Definium Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Institutional Trading of Definium Therapeutics

Several large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after purchasing an additional 3,300 shares during the last quarter. BNP Paribas Financial Markets increased its position in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in Definium Therapeutics in the third quarter valued at approximately $107,000. Finally, Flagship Harbor Advisors LLC bought a new stake in shares of Definium Therapeutics during the fourth quarter worth $117,000. 27.91% of the stock is owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.